NEW YORK –Sophia Genetics and ADC Therapeutics of Lausanne, Switzerland, said today that they will collaborate to identify genomic markers associated with clinical response to an experimental lymphoma treatment.
Under terms of the partnership, Sophia, which also is based near Lausanne, will conduct somatic mutation analysis on more than 4,000 genes in cell-free DNA samples from the blood of patients with refractory diffuse large B-cell lymphoma who participate in ADC's Phase II clinical trial for loncastuximab tesirine, an experimental drug currently dubbed ADCT-402. Sophia's informatics platform will match genomic markers with clinical response to the treatment.
"Our collaboration with Sophia Genetics has the potential to uncover genomic mutations that correlate with clinical response to ADCT-402," ADC Therapeutics Senior VP of Research and Development Patrick van Berkel said in a statement.
"We have observed significant single-agent clinical activity in our pivotal Phase II trial of ADCT-402 in a broad population of patients with relapsed or refractory diffuse large B-cell lymphoma. The insights from this collaboration will allow us to better identify and understand the characteristics of patients who respond best to treatment," van Berkel said.
Earlier this year, Sophia Genetics closed a $77 million Series E funding round.